{"id":851981,"date":"2025-05-16T14:02:26","date_gmt":"2025-05-16T18:02:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/"},"modified":"2025-05-16T14:02:26","modified_gmt":"2025-05-16T18:02:26","slug":"investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/","title":{"rendered":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, May  16, 2025  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether UroGen Pharma Ltd. (\u201cUroGen\u201d or the \u201cCompany\u201d) (NASDAQ: URGN) complied with federal securities laws.\u00a0On May 16, 2025, the FDA stated: \u201cGiven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0<\/p>\n<p align=\"justify\">If you purchased UroGen stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kNGvzNksPJr-z7t8JC9Tn6ifU1Sy1TrbuGZGAt3R06w6rnBJsA7SBXLvZg22CSuisCH7tIIHH1lvytnGN4cU5bj520uPxzQ3DhFYsZ8FRXU=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a> or Joshua Karr, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oiFJgZe-0tD9x3yw0jGzkayy8TekxVNcET8Jo4fajJGzw6Z5nBxPV_QBQdblaiR-Je13NGWn4JqKRPMqy8_wwhUIR3SJQj2BooTdgJ8ywos=\" rel=\"nofollow\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aw080j9NcEOdkHJMm-42W-nhwZBOsK1OOpvtwnMI6dcw2IID3x_IP7q6u1HTHP4Jxw9dapjj3wdqF9EyygsIq_IENDywZGR4PH2-31BoFI5WmiSaObBtyzI3EsyAv57KhNaXBDj4BzAmSRZGjUqnyA==\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/urogen-pharma\/<\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aw080j9NcEOdkHJMm-42W6dmJYADvbj2c7D-xPXAcBnKg7l8Y1ZdJr4mQbF9JOpli3EvUyWFgjs1LeejafXTNzlyb1Cykgklo_jcFw4j4e8=\" rel=\"nofollow\" target=\"_blank\"><u>www.holzerlaw.com<\/u><\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f\u00a0<br \/>\u202f\u00a0<br \/>CONTACT:\u202f\u00a0<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kNGvzNksPJr-z7t8JC9Tn6ifU1Sy1TrbuGZGAt3R06yiC9XQDyx_y6WVkPvBJBduYP2TbAbaP3_G8HKSjjWqW3JzfCF7NNZ-tLfkISX0OZw=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjM4NzQzMTItZmZiNi00NWU0LWIzM2EtYjBiNWM3M2UwZDFiLTExOTIzMzYtMjAyNS0wNS0xNi1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether UroGen Pharma Ltd. (\u201cUroGen\u201d or the \u201cCompany\u201d) (NASDAQ: URGN) complied with federal securities laws.\u00a0On May 16, 2025, the FDA stated: \u201cGiven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased UroGen stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-851981","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether UroGen Pharma Ltd. (\u201cUroGen\u201d or the \u201cCompany\u201d) (NASDAQ: URGN) complied with federal securities laws.\u00a0On May 16, 2025, the FDA stated: \u201cGiven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased UroGen stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua &hellip; Continue reading &quot;INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T18:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC\",\"datePublished\":\"2025-05-16T18:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/\",\"name\":\"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\",\"datePublished\":\"2025-05-16T18:02:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","og_description":"ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether UroGen Pharma Ltd. (\u201cUroGen\u201d or the \u201cCompany\u201d) (NASDAQ: URGN) complied with federal securities laws.\u00a0On May 16, 2025, the FDA stated: \u201cGiven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased UroGen stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua &hellip; Continue reading \"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T18:02:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC","datePublished":"2025-05-16T18:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/"},"wordCount":276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/","name":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=","datePublished":"2025-05-16T18:02:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzM4MCM2OTQ2ODI2IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-investigation-of-urogen-pharma-ltd-urgn-announced-by-holzer-holzer-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer &amp; Holzer, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=851981"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=851981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=851981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=851981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}